← All trials
NCT04194944
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2019
- Primary completion
- Dec 13, 2023
- Completion date
- Aug 13, 2026
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eli LillyLead sponsor
- Eli LillyStudy director
- Loxo OncologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.